Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. has announced a release of voting rights information as notified by the Netherlands Authority for the Financial Markets (AFM). The notification involves T. Rowe Price Group, Inc., which holds a 3.04% capital interest and voting rights in QIAGEN through indirect means. This announcement may impact stakeholders’ perception of QIAGEN’s shareholder structure and influence in the market.
The most recent analyst rating on (QGEN) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is focused on delivering solutions for the analysis of DNA, RNA, and proteins, serving a global market with a presence on major stock exchanges including Frankfurt and NYSE.
Average Trading Volume: 1,465,466
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.3B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.